NCT02455557 2026-02-25
SurVaxM Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
Roswell Park Cancer Institute
Phase 2 Active not recruiting
Clinical Trials
75 trialsNCT03746080 2025-11-14
Whole Brain Radiation Therapy With Standard Temozolomide Chemo-Radiotherapy and Plerixafor in Treating Patients With Glioblastoma
Stanford University
Phase 2 Completed
NCT02337686 2025-08-15
Pembrolizumab in Treating Patients With Recurrent Glioblastoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT01931098 2025-08-11
Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT03137888 2025-08-03
Spectroscopic MRI-Guided Radiation Therapy Planning in Glioblastoma
Emory University
Phase 2 Completed
NCT01894061 2025-02-17
NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma
Case Comprehensive Cancer Center
Phase 2 Completed
NCT01814813 2025-01-24
Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
Alliance for Clinical Trials in Oncology
Phase 2 Terminated
NCT03973918 2024-10-31
BRAF
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT00445965 2024-04-04
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00100802 2023-02-15
Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas
Children's Oncology Group
Phase 2 Completed
NCT01730950 2022-12-29
Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma
Radiation Therapy Oncology Group
Phase 2 Completed
NCT01822275 2022-12-29
GCC 1224
University of Maryland, Baltimore
Phase 2 Terminated
NCT01062425 2022-07-26
Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT03641326 2022-04-19
Sunitinib in Sarcomas of the Central Nervous System
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01004874 2022-04-13
Avastin/Radiation (XRT)/Temozolomide (Temodar) Followed by Avastin/Temodar/Topotecan for Glioblastoma
Duke University
Phase 2 Completed
NCT00003458 2022-03-07
Antineoplaston Therapy in Treating Children With Brain Tumors
Burzynski Research Institute
Phase 2 Completed
NCT00112502 2021-10-18
Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme
M.D. Anderson Cancer Center
Phase 2 Completed
NCT01032200 2021-09-28
Armodafinil in Treating Fatigue Caused By Radiation Therapy in Patients With Primary Brain Tumors
Wake Forest University Health Sciences
Phase 2 Completed
NCT00879437 2021-07-21
Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma
Baylor College of Medicine
Phase 2 Completed
NCT02743078 2021-06-02
Optune® Plus Bevacizumab in Bevacizumab-Refractory Recurrent Glioblastoma
RTOG Foundation, Inc.
Phase 2 Terminated
NCT01740258 2021-01-26
BBP
Duke University
Phase 2 Completed
NCT00006916 2020-10-26
Radiation Therapy Followed by Bleomycin in Treating Adult Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme
Radiation Therapy Oncology Group
Phase 2 Terminated
NCT01013285 2020-09-21
Bevacizumab, Temozolomide, and External Beam Radiation Therapy as First-Line Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT00998010 2020-08-28
Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Jonsson Comprehensive Cancer Center
Phase 2 Completed
NCT00795665 2020-05-12
Bevacizumab and Carmustine in Treating Patients With Relapsed or Progressive High-Grade Glioma
University of California, Davis
Phase 2 Completed
NCT00337207 2020-02-07
Bevacizumab in Treating Patients With Recurrent or Progressive Glioma
Northwestern University
Phase 2 Completed
NCT00892177 2019-10-21
Dasatinib and Bevacizumab in Treating Patients With Recurrent or Progressive High-Grade Glioma or Glioblastoma Multiforme
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00423735 2019-07-24
Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00902577 2019-04-08
MRI and PET/FMISO In Assessing Tumor Hypoxia in Patients With Newly Diagnosed Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 2 Completed
NCT01186406 2019-02-15
Gliadel, XRT, Temodar, Avastin Followed by Avastin, Temodar for Newly Diagnosed Glioblastoma Multiforme (GBM)
Duke University
Phase 2 Terminated
NCT00720356 2018-10-26
Bevacizumab and Erlotinib After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
Northwestern University
Phase 2 Completed
NCT00433381 2018-09-17
Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT01575275 2018-07-31
Aminolevulinic Acid in Visualizing a Tumor During Surgery in Patients With Glioblastoma Multiforme
Case Comprehensive Cancer Center
Phase 2 Terminated
NCT01836549 2018-07-20
Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors
Pediatric Brain Tumor Consortium
Phase 2 Terminated
NCT00052715 2018-07-18
Poly-ICLC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Terminated
NCT00621686 2018-05-08
Bevacizumab and Sorafenib in Treating Patients With Recurrent Glioblastoma Multiforme
Alliance for Clinical Trials in Oncology
Phase 2 Completed
NCT00619112 2018-01-31
Temozolomide in Treating Patients With Recurrent High-Grade Glioma
University of California, San Francisco
Phase 2 Completed
NCT00895180 2017-12-27
Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients With Recurrent Glioblastoma Multiforme
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT01753713 2017-12-12
Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma
Case Comprehensive Cancer Center
Phase 2 Completed
NCT01310868 2017-10-05
Gliadel Wafer and Fluorescence-Guided Surgery With 5-ALA Followed by Radiation Therapy And Temozolomide in Treating Patients With Primary Glioblastoma
University College, London
Phase 2 Completed
NCT00187486 2017-09-05
Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors
University of California, San Francisco
Phase 2 Completed
NCT00540722 2017-08-11
Gossypol in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 2 Completed
NCT00823797 2017-07-07
Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma
University of Washington
Phase 2 Completed
NCT00112866 2017-06-14
Cilengitide in Treating Patients Who Are Undergoing Surgery for Recurrent or Progressive Glioblastoma Multiforme
National Cancer Institute (NCI)
Phase 2 Terminated
NCT01310855 2017-05-31
Cediranib Maleate With or Without Gefitinib in Treating Patients With Recurrent or Progressive Glioblastoma
University College, London
Phase 2 Terminated
NCT01122901 2017-05-03
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Recurrent or Progressive Glioblastoma
National Cancer Institute (NCI)
Phase 2 Terminated
NCT00436436 2017-03-28
O(6)-Benzylguanine and Temozolomide in Treating Patients With Glioblastoma Multiforme That Did Not Respond to Previous Temozolomide and Radiation Therapy
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00459381 2017-03-15
Pazopanib in Treating Patients With Recurrent Glioblastoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00643097 2017-02-01
ACTIVATe
Duke University
Phase 2 Completed
NCT02394665 2017-01-05
Dose Escalated MRSI Guided Radiation Therapy in Glioblastoma
University of Miami
Phase 2 Terminated